PURPOSE: Intestinal mucositis and the closely associated diarrhea are common costly side effects of irinotecan. Cytokine modulators, such as thalidomide and pentoxifylline, are found capable of attenuating intestinal mucositis progression. Nitric oxide (NO) seems to be a key mediator of the antineoplastic drug toxicity. The aim of this study was to investigate the role of NO on the pathogenesis of intestinal mucositis, as well as the participation of cytokines upon inducible nitric oxide synthase (iNOS) expression in irinotecan-induced intestinal mucositis. METHODS: iNOS-knockout (iNOS(-/-)) and C57BL/6 (WT, wild type) animals (n = 5-6) were given either saline or irinotecan (60 mg/kg i.p for 4 days), with or without pretreatment with aminoguanidine (50 mg/kg s.c.), thalidomide (60 mg/kg s.c), infliximab (5 mg/kg i.v.), or pentoxifylline (1.7 mg/kg s.c). On day 5, diarrhea was assessed, and following euthanasia, proximal intestinal samples were obtained for myeloperoxidase (MPO) and iNOS activity, morphometric analysis, western blot and immunohistochemistry to iNOS, cytokine dosage, and for in vitro evaluation of gut contractility. RESULTS: Irinotecan induced severe diarrhea and intestinal smooth muscle over-contractility, accompanied with histopathological changes. Additionally, increased MPO and iNOS activity and iNOS immunoexpression were found in WT animals treated with irinotecan. The rise in MPO, smooth muscle over-contractility, and diarrhea were abrogated in aminoguanidine-treated and iNOS(-/-) mice. Moreover, through western blot, we verified that infliximab and pentoxifylline significantly inhibited irinotecan-induced iNOS expression. In addition, cytokine concentration was found only partially decreased in irinotecan-treated iNOS(-/-) mice when compared with wild-type animals that were given irinotecan. CONCLUSIONS: This study suggests a role of nitric oxide in the pathogenesis of irinotecan-induced intestinal mucositis and also provides evidence for the participation of cytokines on iNOS induction.
PURPOSE:Intestinal mucositis and the closely associated diarrhea are common costly side effects of irinotecan. Cytokine modulators, such as thalidomide and pentoxifylline, are found capable of attenuating intestinal mucositis progression. Nitric oxide (NO) seems to be a key mediator of the antineoplastic drug toxicity. The aim of this study was to investigate the role of NO on the pathogenesis of intestinal mucositis, as well as the participation of cytokines upon inducible nitric oxide synthase (iNOS) expression in irinotecan-induced intestinal mucositis. METHODS:iNOS-knockout (iNOS(-/-)) and C57BL/6 (WT, wild type) animals (n = 5-6) were given either saline or irinotecan (60 mg/kg i.p for 4 days), with or without pretreatment with aminoguanidine (50 mg/kg s.c.), thalidomide (60 mg/kg s.c), infliximab (5 mg/kg i.v.), or pentoxifylline (1.7 mg/kg s.c). On day 5, diarrhea was assessed, and following euthanasia, proximal intestinal samples were obtained for myeloperoxidase (MPO) and iNOS activity, morphometric analysis, western blot and immunohistochemistry to iNOS, cytokine dosage, and for in vitro evaluation of gut contractility. RESULTS:Irinotecan induced severe diarrhea and intestinal smooth muscle over-contractility, accompanied with histopathological changes. Additionally, increased MPO and iNOS activity and iNOS immunoexpression were found in WT animals treated with irinotecan. The rise in MPO, smooth muscle over-contractility, and diarrhea were abrogated in aminoguanidine-treated and iNOS(-/-) mice. Moreover, through western blot, we verified that infliximab and pentoxifylline significantly inhibited irinotecan-induced iNOS expression. In addition, cytokine concentration was found only partially decreased in irinotecan-treated iNOS(-/-) mice when compared with wild-type animals that were given irinotecan. CONCLUSIONS: This study suggests a role of nitric oxide in the pathogenesis of irinotecan-induced intestinal mucositis and also provides evidence for the participation of cytokines on iNOS induction.
Authors: Luana David do Carmo; Gisele de Fátima Pinheiro Rangel; Liviane Maria Alves Rabelo; Tamiris de Fátima Goebel de Souza; Roberto César Pereira Lima Júnior; Deysi Viviana Tenazoa Wong; Renata Ferreira de Carvalho Leitão; Alfredo Augusto Vasconcelos da Silva; Pedro Jorge Caldas Magalhães; Andréa Santos Costa; Dyély de Carvalho Oliveira Campos; Nylane Maria Nunes de Alencar; Hermógenes David de Oliveira Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2022-07-01 Impact factor: 3.195
Authors: R C P Lima-Júnior; H C Freitas; D V T Wong; C W S Wanderley; L G Nunes; L L Leite; S P Miranda; M H L P Souza; G A C Brito; P J C Magalhães; M M Teixeira; F Q Cunha; R A Ribeiro Journal: Br J Pharmacol Date: 2014-05 Impact factor: 8.739
Authors: Richard A Forsgård; Vannina G Marrachelli; Katri Korpela; Rafael Frias; Maria Carmen Collado; Riitta Korpela; Daniel Monleon; Thomas Spillmann; Pia Österlund Journal: Cancer Chemother Pharmacol Date: 2017-06-23 Impact factor: 3.333
Authors: Ludmila T Nogueira; Deiziane V S Costa; Antoniella S Gomes; Conceição S Martins; Angeline M H P Silva; Juliana M Coelho-Aguiar; Patrícia Castelucci; Roberto C P Lima-Júnior; Renata F C Leitão; Vivaldo Moura-Neto; Gerly A C Brito Journal: J Neuroinflammation Date: 2017-04-07 Impact factor: 8.322
Authors: Deysi V T Wong; Roberto C P Lima-Júnior; Cibele B M Carvalho; Vanessa F Borges; Carlos W S Wanderley; Amanda X C Bem; Caio A V G Leite; Maraiza A Teixeira; Gabriela L P Batista; Rangel L Silva; Thiago M Cunha; Gerly A C Brito; Paulo R C Almeida; Fernando Q Cunha; Ronaldo A Ribeiro Journal: PLoS One Date: 2015-10-06 Impact factor: 3.240
Authors: R Guabiraba; A G Besnard; G B Menezes; T Secher; M S Jabir; S S Amaral; H Braun; R C P Lima-Junior; R A Ribeiro; F Q Cunha; M M Teixeira; R Beyaert; G J Graham; F Y Liew Journal: Mucosal Immunol Date: 2014-01-15 Impact factor: 7.313